LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Home・Akcijų sąrašas・United Therapeutics Corp

United Therapeutics Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

581.65 2.16

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

568.6

Max

583.49

Pagrindiniai rodikliai
By Trading Economics
Pajamos	26M 364M
Pardavimai	-9.3M 790M
P/E Sektoriaus vid.	20.877 49.8
Pelno marža	46.102
Darbuotojai	1,400
EBITDA	61M 524M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+13.68% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-07-29

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	3.2B 25B
Ankstesnė atidarymo kaina	579.49
Ankstesnė uždarymo kaina	581.65

Naujienos nuotaikos

By Acuity

50%

150 / 346 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

292.345 / 309.245 Palaikymas ir pasipriešinimas

United Therapeutics Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-12 22:50; UTC

Uždarbis

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

2026-05-12 22:49; UTC

Uždarbis

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

2026-05-12 22:32; UTC

Uždarbis

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

2026-05-12 23:48; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

2026-05-12 22:57; UTC

Rinkos pokalbiai

Uždarbis

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

2026-05-12 22:26; UTC

Uždarbis

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

2026-05-12 22:25; UTC

Uždarbis

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

2026-05-12 22:25; UTC

Uždarbis

Aristocrat Leisure Interim Dividend A$0.50/Security

2026-05-12 22:24; UTC

Uždarbis

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

2026-05-12 22:23; UTC

Uždarbis

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

2026-05-12 22:23; UTC

Uždarbis

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

2026-05-12 22:19; UTC

Uždarbis

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

2026-05-12 22:14; UTC

Uždarbis

CBA: Business Lending Continued to Grow Above System>CBA.AU

2026-05-12 22:14; UTC

Uždarbis

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

2026-05-12 22:13; UTC

Uždarbis

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

2026-05-12 22:12; UTC

Uždarbis

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

2026-05-12 22:12; UTC

Uždarbis

CBA 3Q New Home Loan Funding A$45B>CBA.AU

2026-05-12 22:11; UTC

Uždarbis

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

2026-05-12 22:11; UTC

Uždarbis

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

2026-05-12 22:10; UTC

Uždarbis

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

2026-05-12 22:09; UTC

Uždarbis

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

2026-05-12 22:09; UTC

Uždarbis

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

2026-05-12 22:08; UTC

Uždarbis

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

2026-05-12 22:07; UTC

Uždarbis

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

2026-05-12 22:06; UTC

Uždarbis

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

2026-05-12 22:06; UTC

Uždarbis

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

2026-05-12 22:05; UTC

Uždarbis

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

2026-05-12 22:04; UTC

Uždarbis

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

2026-05-12 22:04; UTC

Uždarbis

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

2026-05-12 22:04; UTC

Uždarbis

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Akcijų palyginimas

Kainos pokytis

United Therapeutics Corp Prognozė

Kainos tikslas

By TipRanks

13.68% į viršų

12 mėnesių prognozė

Vidutinis 647.83 USD 13.68%

Aukščiausias 738 USD

Žemiausias 516 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines United Therapeutics Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

13 ratings

Pirkti

Laikyti

Parduoti

Remiantis 13 analitikų, pateikusių United Therapeutics Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

292.345 / 309.245Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

150 / 346 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.